LLY vs MRNA
By Alex · Tickerpine
Eli Lilly and Company vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | MRNA |
|---|---|---|
| Price | $1,208.12 | $67.27 |
| Market cap | $1.08T | $26.69B |
| P/E ratio | 42.9 | — |
| ROE | 107.46% | -36.56% |
| Profit margin | 34.99% | -143.55% |
| Revenue growth | 55.50% | 260.20% |
| Dividend yield | 0.57% | — |
| Beta | 0.52 | 1.03 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs MRNA in plain English
- LLY is the bigger company — about 40.4× the market cap of MRNA.
- LLY earns a higher return on equity (107% vs -37%).
- MRNA is growing revenue faster (260% vs 56%).
- LLY pays a dividend (0.57%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.